GET DAILY SIGNALSAvalo Therapeutics (AVTX) Reports Narrower Third-Quarter Loss With Substantial Cash Reserves
Key Takeaways
- Avalo Therapeutics reported a net loss of $18.95 million for the third quarter of 2026, narrowing from a $30.63 million loss in the same period a year earlier.
- Net loss per share came in at $0.34, compared with $2.19 in the prior-year quarter, reflecting both a lower loss and a significantly higher share count following the company's May 2026 equity offering.
- The company ended the quarter with roughly $462.8 million in cash, cash equivalents, and investments, which management says is expected to fund operations into 2029.
- Avalo generated no product revenue during the period, consistent with its status as a clinical-stage biotechnology company.
- Research and development expenses rose to about $15.0 million, while general and administrative expenses increased to roughly $8.4 million.
Earnings Context and Pipeline Focus
Avalo Therapeutics is a clinical-stage biotechnology company focused on developing IL-1β (interleukin-1 beta) based treatments for immune-mediated inflammatory diseases. Because the company has no approved products yet, its quarterly results matter less for revenue and more for cash position, spending discipline, and pipeline execution. This report arrives shortly after the company announced positive Phase 2 LOTUS trial results for its lead asset, abdakibart, in hidradenitis suppurativa (HS), a chronic inflammatory skin condition. Following that data, Avalo completed a $431.3 million public offering, substantially strengthening its balance sheet. Investors are watching closely to see how the company deploys that capital as it prepares to advance abdakibart into a registrational Phase 3 program. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Quarterly Results Breakdown
For the third quarter ended September 30, 2026, AVTX reported a net loss of $18.95 million, an improvement from the $30.63 million net loss recorded in the third quarter of 2025. Basic and diluted net loss per share was $0.34, versus $2.19 in the year-ago quarter. The company reported no revenue during the period, which is typical for a pre-commercial biotech. Research and development expenses were approximately $15.0 million, up from about $13.6 million a year earlier, driven by chemistry, manufacturing, and controls (CMC) work for abdakibart and the next-generation candidate AVTX-010, as well as higher stock-based compensation. General and administrative expenses rose to roughly $8.4 million from about $5.6 million. As of September 30, 2026, cash, cash equivalents, and investments totaled approximately $462.8 million.
Market Reaction and Investor Focus
Investor sentiment around AVTX has been shaped more by its pipeline progress than by its income statement. The company's May 2026 announcement of positive Phase 2 LOTUS results for abdakibart was a defining catalyst, followed by a sizable equity raise that bolstered its cash position. Against that backdrop, the third-quarter loss of $0.34 per share was narrower than many analyst expectations, which generally pointed to a wider per-share loss. Because the reported figure was aided by a non-cash benefit tied to a change in the fair value of a derivative liability, investors may focus less on the headline earnings beat and more on the company's cash runway and its timeline for initiating the Phase 3 program.
Forward Catalysts and Monitoring Points
The most important forward-looking catalyst for Avalo is the planned initiation of a registrational Phase 3 trial for abdakibart in hidradenitis suppurativa. Management has indicated it expects to begin this program in the first half of 2027, following regulatory feedback. Investors will be watching for clarity on trial design, enrollment timelines, and any guidance on when data might read out.
A second area to monitor is the company's next-generation pipeline candidate, AVTX-010, a long-acting anti-IL-1β antibody. Avalo has said it plans to submit an Investigational New Drug (IND) application for AVTX-010 in the first half of 2027. An accepted IND would mark another step in broadening the company's development efforts beyond abdakibart.
On the financial side, the company's cash, cash equivalents, and investments of approximately $462.8 million are expected to fund operations into 2029. However, as the Phase 3 program scales up, research and development spending is likely to rise, and the pace of that increase will be an important gauge of the company's capital efficiency. Operating cash burn in the first nine months of 2026 was about $49.2 million, a figure worth tracking as pivotal-stage development accelerates. From what I see, these milestones will determine how effectively the strengthened balance sheet translates into clinical progress.
Exploring AI Tools in Biotech Analysis
In my own research process, I often turn to Tickeron’s AI Screener when evaluating clinical-stage companies like this one. It helps filter for relevant technical patterns, fundamentals, and sector trends, which can surface comparable names or highlight broader market context that might otherwise take more time to assemble manually. This approach keeps the focus on data-driven comparisons rather than isolated headline numbers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AVTX's Indicator enters downward trend
The Aroon Indicator for AVTX entered a downward trend on November 03, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 297 similar instances where the Aroon Indicator formed such a pattern. In 263 of the 297 cases the stock moved lower. This puts the odds of a downward move at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 50-day moving average for AVTX moved below the 200-day moving average on October 22, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +10.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where AVTX advanced for three days, in 199 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
AVTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. AVTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.793) is normal, around the industry mean (2.788). P/E Ratio (-1.503) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (19.030) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. AVTX's P/S Ratio (10000.000) is very high in comparison to the industry average of (440.869).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical stage biopharmaceutical company
Industry Biotechnology
Advertisement